PureTech to Present at The Barclays Global Healthcare Conference
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) announced that Chief Financial Officer George Farmer, Ph.D., will present at the Barclays Global Healthcare Conference on March 10th at 10:20 AM EST. A webcast of the presentation will be available on the company's investor relations page. PureTech focuses on developing innovative medicines for critical diseases, boasting a pipeline of 24 products, including two that received FDA clearance and European marketing authorization. The company leverages unique insights into the brain, immune, and gut systems to drive its research and development efforts.
- None.
- None.
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced that George Farmer, Ph.D., its Chief Financial Officer, will present at the Barclays Global Healthcare Conference on Wednesday, March 10th at 10:20 AM EST. A webcast of the presentation will be available at https://investors.puretechhealth.com/events-presentations.
PureTech’s Chief Financial Officer, George Farmer, Ph.D., will present at the Barclays Global Healthcare Conference on Wednesday, March 10th at 10:20 AM EST. (Graphic: Business Wire)
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including intractable cancers, lymphatic and gastrointestinal diseases, central nervous system disorders and inflammatory and immunological diseases, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech's Founded Entities, as of the date of PureTech's most recently filed Registration Statement on Form 20-F, was comprised of 24 products and product candidates, including two that have received FDA clearance and European marketing authorization. All of the underlying programs and platforms that resulted in this pipeline of product candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on the Company's unique insights into the biology of the brain, immune and gut, or BIG, systems and the interface between those systems, referred to as the BIG Axis.
For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, our expectations regarding the potential therapeutic benefits of our product candidates and those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210303005194/en/
FAQ
When will George Farmer present at the Barclays Global Healthcare Conference for PureTech Health?
Where can I watch the webcast of PureTech Health's presentation at the Barclays Conference?
What does PureTech Health focus on in terms of drug development?
What is the product pipeline of PureTech Health as of the latest report?
What are the unique insights driving PureTech Health's research and development?
